Posted by Michael Wonder on 17 Dec 2016
Novartis receives positive CHMP recommendation for Ilaris to treat rare diseases in adults and children called Periodic Fever Syndromes
16 December 2016 - Periodic Fever Syndromes are rare diseases mostly affecting children and cause recurrent and disabling fevers with potentially life-threatening complications.
Novartis announced today that the CHMP has recommended approval of Ilaris (canakinumab) in Europe to treat three rare and distinct Periodic Fever Syndromes.
If approved, Ilaris will be the first and only approved biologic treatment in Europe for Tumour Necrosis Factor-Receptor Associated Periodic Syndrome, Hyperimmunoglobulin D Syndrome/Mevalonate Kinase Deficiency and Familial Mediterranean Fever.
